• Prof. Anand Deva’s presentation highlighted a high breast volume retention rate of 87% and a low complication rate after one year of patient follow-up.
  • Successful vascularization and vessel development were observed in a two-year follow-up.
  • The 3D-printed resorbable scaffold is designed to maintain both the volume and shape of autologous fat in the long term.

Leipzig, Germany / Brisbane, Australia, March 24, 2025 – BellaSeno, an ISO 13485-certified medtech company specializing in resorbable scaffolds using additive manufacturing, announced that Prof. Anand Deva presented new clinical data regarding BellaSeno’s innovative, 3D-printed, resorbable breast scaffolds at The Aesthetic MEET 2025 conference held in Austin, TX, USA.

In an Australian clinical trial that began in 2022, 19 patients received BellaSeno’s resorbable breast scaffolds, made from polycaprolactone, after having their failed silicone breast implants removed. The one-year follow-up results indicated 87% breast volume retention, minimal complications, a high quality of life, natural softness, and improvements in both physical and psychological well-being. Furthermore, there were no recorded complications typically associated with silicone implants or fat grafting, such as capsular contractures, infections, necrosis, calcification, oil cysts, or scaffold removals. Prof. Deva and his team, observing patients at the two-year mark, noted successful vascularization and the development of a vessel network within the newly formed breast tissue inside the scaffold.

“These clinical results suggest that BellaSeno has created a safe and effective alternative to silicone breast implants,” stated Prof. Deva. “BellaSeno’s implants enhance and safeguard the body’s natural regenerative abilities, replacing or augmenting tissue with similar tissue.”

“This marks another significant achievement, demonstrating that our pioneering method provides a risk-optimized, high-quality solution for patients who have experienced issues with silicone breast implants, offering them a natural option,” stated Mohit Chhaya, CEO of BellaSeno. “We are pleased that our scaffolds have allowed the breasts to retain their shape, volume, and form over time, along with achieving softness, which is another critical measure of performance.”

Professor Anand Deva is the Discipline Head of Cosmetic, Plastic and Reconstructive Surgery at Macquarie University, Australia, and the founder of Integrated Breast Health Clinics, in partnership with government and industry. He is dedicated to scientific innovation and translational research aimed at enhancing clinical practices and patient outcomes.

###

About BellaSeno
BellaSeno GmbH, established in 2015, is based at the BioCity campus in Leipzig, Germany, and has a subsidiary in Brisbane, Australia. The company is developing innovative resorbable soft tissue and bone reconstruction implants using additive manufacturing (3D-printing) under ISO 13485 certification. The company has secured considerable financial backing from private investors, the Saxony Development Bank (SAB), the European Fund for Regional Development (EFRE), Germany’s Federal Ministry of Education and Research (BMBF), and the Australian government. The company has received co-funding from tax resources based on the budget approved by the members of the Saxony State Parliament.


Contact BellaSeno
BellaSeno GmbH
Dr. Mohit Chhaya
mohit.chhaya@bellaseno.com
Tel.: +49 176 2283 9583

Media Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68

“`